Picture loading failed.

Anti-IL17RA therapeutic antibody (Pre-made Brodalumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Brodalumab (trade name Siliq in the US and Kyntheum in Europe) is a human monoclonal antibody designed for the treatment of inflammatory diseases.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-082-1mg 1mg 3090
GMP-Bios-ab-082-10mg 10mg 21890
GMP-Bios-ab-082-100mg 100mg 148000
GMP-Bios-ab-082-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-IL17RA therapeutic antibody (Pre-made Brodalumab biosimilar,Whole mAb)
INN Name Brodalumab
TargetIL17RA
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2011
Year Recommended2012
CompaniesAmgen;AstraZeneca;Bausch Health Companies;Kyowa Hakko Kirin;LEO Pharma
Conditions ApprovedErythrodermic psoriasis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis;Psoriasis
Conditions ActiveAxial Spondylarthritis;Systemic scleroderma;Palmoplantar pustulosis
Conditions DiscontinuedAsthma;Crohn's disease;Rheumatoid arthritis
Development TechAbgenix XenoMouse